RTP Mobile Logo
Submitted by web@researchtop... on Mon, 04/27/2020 - 13:45
BiomarkersLung20

Roundtable Discussion

Topic 1: Biomarker testing and therapeutic decision-making for patients with non-small cell lung cancer (NSCLC)
Topic 2: Case: A woman in her late 80s, a never smoker, is diagnosed with metastatic adenocarcinoma of the lung with an EGFR exon 21 L858R mutation
Topic 3: Therapeutic approach for patients with NSCLC and EGFR tumor mutations
Topic 4: Results of the Phase III FLAURA trial evaluating osimertinib versus gefitinib or erlotinib for untreated advanced NSCLC with EGFR tumor mutations
Topic 5: Pneumonitis and cardiotoxicity associated with osimertinib in patients with NSCLC
Topic 6: Second-line therapy for patients after disease progression on osimertinib
Topic 7: Efficacy and tolerability of immune checkpoint inhibitors in patients with NSCLC harboring an actionable genomic alteration
Topic 8: Resistance mutations in patients who experience disease progression on osimertinib
Topic 9: Genomic profiling for patients with metastatic nonsquamous NSCLC; optimal testing platforms
Topic 10: Evaluation of biomarkers in patients with squamous cell carcinoma of the lung
Topic 11: Targeting KRAS G12C and MET exon 14 splice mutations
Topic 12: Case: A woman in her mid-50s who presents with cough, dyspnea and respiratory distress is diagnosed with metastatic adenocarcinoma of the lung with an EGFR exon 21 L858R mutation
Topic 13: Considerations for switching to an EGFR tyrosine kinase inhibitor (TKI) in a symptomatic patient initially started on chemotherapy prior to the identification of an EGFR tumor mutation
Topic 14: Role of liquid biopsy in monitoring patients who are receiving EGFR TKI therapy
Topic 15: Activity of immune checkpoint inhibitors in patients with NSCLC and targetable genomic alterations
Topic 16: Results of the IMpower150 and IMpower130 trials of atezolizumab with bevacizumab/chemotherapy and atezolizumab with chemotherapy, respectively, as first-line treatment for metastatic nonsquamous NSCLC
Topic 17: Immune checkpoint inhibitors for patients with advanced lung cancer with oncogenic driver alterations: Results from the IMMUNOTARGET registry
Topic 18: Toxicities associated with the use of targeted therapy after immunotherapy in patients with NSCLC; risk of pneumonitis with durvalumab and osimertinib
Topic 19: Increased hepatotoxicity associated with sequential immune checkpoint inhibitor and crizotinib therapy for patients with NSCLC
Topic 20: Therapeutic approach for patients with locally advanced NSCLC with EGFR tumor mutations who experience disease relapse after treatment with durvalumab
Topic 21: Cardiac toxicity associated with immune checkpoint inhibitors
Topic 22: Monitoring for and management of the cardiac side effects of immune checkpoint inhibitors
Topic 23: Case: A man in his late 70s with adenocarcinoma of the lung and brain metastases is found through next-generation sequencing to have an EGFR exon 21 L858R mutation, HER2 amplification and high PD-L1 expression
Topic 24: Use of liquid biopsy to detect genomic alterations in patients with NSCLC
Topic 25: FGFR alterations in patients with NSCLC
Topic 26: Targeting HER2 alterations in patients with lung cancer
Topic 27: Efficacy of EGFR TKIs in patients with lung cancer and CNS metastases; sequencing stereotactic radiosurgery and EGFR TKIs
Topic 28: Diagnosis and management of radiation necrosis in patients with lung cancer
Topic 29: Preservation of neurocognitive function during whole-brain radiation therapy with hippocampal sparing for patients with NSCLC and brain metastases
Topic 30: Case: A woman in her early 80s with adenocarcinoma of the lung with an EGFR exon 21 L858R mutation and metastases to the brain receives osimertinib as first-line therapy
Topic 31: Activity of EGFR TKIs in patients with brain metastases; CNS penetration and dosing of osimertinib
Topic 32: Results of the BLOOM study evaluating osimertinib for patients with leptomeningeal metastases from NSCLC with EGFR tumor mutations
Topic 33: Targeting EGFR exon 20 insertions with TAK-788 and poziotinib
Topic 34: Results of the Phase III ALEX study evaluating alectinib and the Phase III ALTA-1L study investigating brigatinib for patients with advanced NSCLC and ALK rearrangements
Topic 35: Sequencing ALK inhibitors for patients with NSCLC with ALK rearrangements
Topic 36: Tolerability of brigatinib, alectinib, ceritinib and lorlatinib in patients with NSCLC with ALK rearrangements
Topic 37: Emerging data with targeted therapies for patients with NSCLC in the (neo)adjuvant setting
Topic 38: Ongoing (neo)adjuvant trials of targeted therapies for patients with locally advanced NSCLC
Topic 39: Perspective on emerging data from studies evaluating adjuvant targeted therapy for advanced NSCLC
Topic 40: Risks associated with neoadjuvant therapy for patients with advanced NSCLC
Topic 41: Case: A woman in her late 50s with metastatic NSCLC with a RET rearrangement receives carboplatin/pemetrexed/bevacizumab followed by selpercatinib upon disease progression
Topic 42: Activity of the selective RET inhibitors selpercatinib and pralsetinib; detection of RET alterations in patients with NSCLC
Topic 43: Duration of response, CNS penetration and tolerability profile of RET inhibitors
Topic 44: Efficacy of pemetrexed-based chemotherapy regimens for patients with NSCLC with RET fusions
Topic 45: Case: A woman in her mid-50s with metastatic NSCLC with a BRAF V600E tumor mutation attains a good response to dabrafenib/trametinib after experiencing disease progression on multiple lines of therapy
Topic 46: Activity and tolerability of BRAF and MEK inhibitors in patients with NSCLC with BRAF tumor mutations
Topic 47: Duration of therapy with BRAF and MEK inhibitors
Topic 48: Biology, detection and management of NSCLC with MET exon 14 mutations
Topic 49: Significance of HER2 mutations in patients with lung cancer
Topic 50: Targeting NTRK gene fusions with larotrectinib and entrectinib
Topic 51: Therapeutic options for patients with NSCLC and ROS1 translocations
 
CLINICAL INVESTIGATORS
 
Justin F Gainor, MD
Director, Center for Thoracic Cancers
Director of Targeted Immunotherapy
Termeer Center for Targeted Therapies
Massachusetts General Hospital
Assistant Professor
Harvard Medical School
Boston, Massachusetts
 
Matthew Gubens, MD, MS
Associate Professor
Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California
 
Geoffrey R Oxnard, MD
Associate Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
 
Heather Wakelee, MD
Professor of Medicine
Division of Oncology
Faculty Director
Stanford Cancer Clinical Trials Office
Stanford University School of Medicine
Stanford Cancer Institute
Stanford, California
 
CONSULTING ONCOLOGISTS
 
Isaac Levy, MD
Memorial Healthcare System
Hollywood, Florida
 
Estelamari Rodriguez, MD, MPH
Associate Director for
Community Outreach-Thoracic Oncology
Sylvester Comprehensive Cancer Center
University of Miami
Miller School of Medicine
Miami, Florida
 
MODERATOR
 
Neil Love, MD
Research To Practice
Miami, Florida